<DOC>
	<DOCNO>NCT01289574</DOCNO>
	<brief_summary>To evaluate safety efficacy topical 0.1 % 0.025 % ASC-J9 cream apply twice daily facial acne compare vehicle control .</brief_summary>
	<brief_title>Topical ASC-J9 Cream Acne</brief_title>
	<detailed_description>Approximately 180 patient least 12 year age facial acne randomize twice daily topical treatment 0.1 % 0.025 % ASC-J9 cream vehicle control 12 week . Patients return clinic Weeks 2 , 4 , 8 12 4 week last dose study drug evaluation acne status safety parameter .</detailed_description>
	<criteria>Key At least 12 year age time enrollment Facial acne , : 1 . 2060 inflammatory facial lesion ( papules/pustules/nodules/cysts ) ; 2 . 20100 noninflammatory facial lesion ( open close comedo ) ; 3 . No 2 nodules/cysts face ( defined inflammatory lesion great equal 5 mm diameter ) ; 4 . Investigator 's Global Assessment ( IGA ) acne score 3 4 . Key Females pregnant breastfeed Skin disease acne vulgaris Use topical systemic treatment acne Other significant medical condition clinically significant abnormal laboratory test result .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>androgen receptor degradation enhancer</keyword>
</DOC>